NEW YORK (GenomeWeb) – Natera is aiming to raise $75 million in a follow-on public offering of shares of its common stock, the firm reported after the close of the market on Tuesday. It also expects to grant underwriters a 30-day option to purchase up to an additional $11.25 million worth of common stock.
JP Morgan, Morgan Stanley, and Cowen are acting as joint book-running managers for the offering, which will be made only through a prospectus and related prospectus supplement, copies of which can be obtained from JP Morgan Securities.
The San Carlos, California-based molecular diagnostics firm went public in 2015, selling 10 million shares of common stock at $18 per share to raise $180 million in its initial public offering.
In Wednesday morning trading, Natera's stock was up more than 2 percent at $21.56 per share.